Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 May 20;332(7551):1177-81.
doi: 10.1136/bmj.38803.528113.55. Epub 2006 May 5.

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine

Sarah E McDowell  1 , Jamie J Coleman, R E Ferner
Affiliations
Meta-Analysis

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine

Sarah E McDowell et al. BMJ. .

Abstract

Objective: To review the evidence for ethnic differences in susceptibility to adverse drug reactions (ADRs) to cardiovascular drugs.

Design: Systematic review and meta-analysis.

Data sources: We searched Medline and Embase to March 2005. Reference lists of identified articles were hand searched for further relevant articles.

Review methods: Studies were eligible for inclusion if they included at least two ethnic groups and one or more ADRs. We excluded case reports and case series.

Results: 564 studies contained some description of ethnicity and an ADR, and 132 of them related to cardiovascular therapies. Twenty four studies provided data for ADRs for at least two ethnic groups and were therefore eligible for inclusion. In pooled analyses the relative risk of angio-oedema from angiotensin converting enzyme (ACE) inhibitors in black compared with non-black patients was 3.0 (95% confidence interval 2.5 to 3.7); the relative risk of cough from ACE inhibitors was 2.7 (1.6 to 4.5) in East Asian compared with white patients; and the relative risk of intracranial haemorrhage with thrombolytic therapy was 1.5 (1.2 to 1.9) in black compared with non-black patients.

Conclusion: Patients from different ethnic groups have different risks for important ADRs to cardiovascular drugs. Ethnic group may therefore be one determinant of harms of a given treatment in the individual patient, either because it acts as a surrogate measure of genetic make up or because cultural factors alter the risk. Data are sparse, and regulators should consider asking for better data before licensing.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Flow chart of study selection
Fig 2
Fig 2
Pooled analysis of proportion of black and non-black patients with angio-oedema associated with use of ACE inhibitors
Fig 3
Fig 3
Pooled analysis of proportion of East Asian and white patients with cough associated with use of ACE inhibitors
Fig 4
Fig 4
Pooled analysis of proportion of black and non-black patients with cough associated with use of ACE inhibitors
Fig 5
Fig 5
Pooled analysis of proportion of black and non-black patients with intracranial haemorrhage associated with thrombolytic treatment
See this image and copyright information in PMC

Comment in

References

    1. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997;277: 307-11. - PubMed
    1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274: 29-34. - PubMed
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329: 15-9. - PMC - PubMed
    1. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003;327: 1222-5. - PMC - PubMed
    1. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286: 2270-9. - PubMed

Publication types

MeSH terms

Substances